Skip to main content

Advertisement

SpringerLink
Log in

Pharmacogenetics of response to statins: Where do we stand?

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Cardiovascular disease is one of the leading causes of death, especially in developed countries. Blood cholesterol lowering by way of statin therapy is a common risk-lowering therapy. The risk reduction for coronary artery disease for patients using statins is 27%. These reductions, however, are average effects for all patients included in the trials. There is notable interindividual variation in response to statins, and the origins of this variation are poorly understood. Pharmacogenetics seeks to determine the role of genetic factors in variation of drug response. In patients with primary hypercholesterolemia, 23 studies have examined the effects of genetic polymorphisms at 20 different loci on the lipid response to statin treatment, and 18 studies examined genetic polymorphisms involved in the benefits of statin therapy in the prevention of cardiovascular disease. Even though many studies have been performed, few results have been replicated. It is our contention that larger sample sizes and consideration of multiple genes are needed in the field of pharmacogenetics of statin response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. McGovern PG, Pankow JS, Shahar E, et al.: Recent trends in acute coronary heart disease—mortality, morbidity, medical care, and risk factors. N Engl J Med 1996, 334:884–890.

    Article  PubMed  CAS  Google Scholar 

  2. Dobson AJ, McElduff P, Heller R, et al.: Changing patterns of coronary heart disease in the hunter region of New South Wales, Australia. J Clin Epidemiol 1999, 52:761–771.

    Article  PubMed  CAS  Google Scholar 

  3. Sacks F, Pfeffer MA, Moye LA, et al.: The effect of pravastatine on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009.

    Article  PubMed  CAS  Google Scholar 

  4. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatine in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1307.

    Article  PubMed  CAS  Google Scholar 

  5. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatine in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998, 279:1615–1622.

    Article  PubMed  CAS  Google Scholar 

  6. Anonymous: MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20,536 high risk individuals; a randomized placebo controlled trial. Lancet 2002, 360:7–22.

  7. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations; in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) a multicentre randomised controlled trial. Lancet 2003, 361:1149–1158.

    Article  PubMed  CAS  Google Scholar 

  8. Anonymous: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatine Survival Study. Lancet 1994, 344:1383–1389.

    Google Scholar 

  9. Anonymous: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.

    Google Scholar 

  10. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623–1630.

    Article  PubMed  CAS  Google Scholar 

  11. Cheung BM, Lauder IJ, Lau CP, Kumana CR: Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004, 57:640–651.

    Article  PubMed  CAS  Google Scholar 

  12. Sadee W: Pharmacogenomics. BMJ 1999, 319:1286.

    Google Scholar 

  13. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al.: Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002, 163:213–222.

    Article  Google Scholar 

  14. Kajinami K, Takekoshi N, Brousseau ME, Schaefer EJ: Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management. Atherosclerosis 2004, 177:219–234.

    Article  PubMed  CAS  Google Scholar 

  15. Schmitz G, Drobnik W: Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy. Clin Chem Lab Med 2003, 41:581–589.

    Article  PubMed  CAS  Google Scholar 

  16. Dornbrook-Lavender KA, Pieper JA: Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy. Cardiovasc Drugs Ther 2003, 17:75–82.

    Article  PubMed  CAS  Google Scholar 

  17. Lefer AM, Scalia R, Lefer DJ: Vascular effects of HMG Co-A reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001, 49:281–287.

    Article  PubMed  CAS  Google Scholar 

  18. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996, 348:1079–1082.

    Article  PubMed  CAS  Google Scholar 

  19. Psaty BM, Weiss NS, Furberg CD, et al.: Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999, 282:786–790.

    Article  PubMed  CAS  Google Scholar 

  20. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet Med 2002, 4:45–61.

    PubMed  CAS  Google Scholar 

  21. Kuivenhoven J, Jukema JW, Zwinderman AH, et al.: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998, 338:86–93.

    Article  PubMed  CAS  Google Scholar 

  22. Carlquist JF, Muhlestein JB, Horne BD, et al.: The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J 2003, 146:1007–1014.

    Article  PubMed  CAS  Google Scholar 

  23. Bray PF, Cannon CP, Goldschmidt-Clermont P, et al.: The platelet P1(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001, 88:347–352.

    Article  PubMed  CAS  Google Scholar 

  24. Maitland-van der Zee AH, Stricker BH, Klungel OH, et al.: Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis 2004, 175:377–379.

    Article  CAS  Google Scholar 

  25. Davis BR, Ford CE, Boerwinkle E, et al.: Imputing genetreatment interactions when the genotype distribution is unknown using case-only and putative placebo analyses—a new method for the Genetics of Hypertension Associated Treatment (GenHAT) study. Stat Med 2004, 23:2413–2427.

    Article  PubMed  Google Scholar 

  26. Gresser U, Gathof BS: Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke—comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies. Eur J Med Res 2004, 9:1–17.

    PubMed  CAS  Google Scholar 

  27. Maitland-van der Zee AH, Turner ST, Schwartz GL, et al.: Multilocus approach to the pharmacogenetics of thiazide diuretics. Pharmacogenetics 2005, In press.

  28. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA: Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991, 7:403–422.

    Article  PubMed  CAS  Google Scholar 

  29. Grobbee DE, Hoes AW: Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997, 315:1151–1154.

    PubMed  CAS  Google Scholar 

  30. Psaty BM, Koepsell TD, Lin D, et al.: Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999, 47:749–754.

    PubMed  CAS  Google Scholar 

  31. Chasman DI, Posada D, Subrahmanyan L, et al.: Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004, 291:2821–2827.

    Article  PubMed  CAS  Google Scholar 

  32. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995, 57:289–300.

    Google Scholar 

  33. Hoh J, Wille A, Ott J: Trimming, weighting, and grouping SNPs in human case-control association studies. Genome Res 2001, 11:2115–2119.

    Article  PubMed  CAS  Google Scholar 

  34. Bureau A, Dupuis J, Falls K, et al.: Identifying SNPs predictive of phenotype using random forests. Genet Epidemiol 2005, 28:171–182.

    Article  PubMed  Google Scholar 

  35. Rodin A, Brown A, Clark A, et al.: Mining genetic epidemiology data with Bayesian networks II: application to ApoE gene variants and plasma lipid levels. J Computational Biol 2005, In press.

  36. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, et al.: Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995, 113:157–166.

    Article  PubMed  CAS  Google Scholar 

  37. Nestel P, Simons L, Barter P, et al.: A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis 1997, 129:231–239.

    Article  PubMed  CAS  Google Scholar 

  38. Ballantyne CM, Herd JA, Stein EA, et al.: Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol 2000, 36:1572–1578.

    Article  PubMed  CAS  Google Scholar 

  39. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al.: Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001, 158:183–193.

    Article  PubMed  CAS  Google Scholar 

  40. Sanllehy C, Casals E, Rodriguez-Villar C, et al.: Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 1998, 47:560–565.

    Article  PubMed  CAS  Google Scholar 

  41. Pena R, Lahoz C, Mostaza JM, et al.: Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J Intern Med 2002, 251:518–525.

    Article  PubMed  CAS  Google Scholar 

  42. Ojala JP, Helve E, Ehnholm C, et al.: Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia. J Intern Med 1991, 230:397–405.

    Article  PubMed  CAS  Google Scholar 

  43. Gerdes LU, Gerdes C, Kervinen K, et al.: The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the scandinavian simvastatin survival study. Circulation 2000, 101:1366–1371.

    PubMed  CAS  Google Scholar 

  44. Maitland-van der Zee AH, Stricker BH, Klungel OH, et al.: The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics 2002, 12:647–653.

    Article  Google Scholar 

  45. Salazar LA, Hirata MH, Quintao EC, Hirata RD: Lipidlowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia. J Clin Lab Anal 2000, 14:125–131.

    Article  PubMed  CAS  Google Scholar 

  46. Guzman EC, Hirata MH, Quintao EC, Hirata RD: Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease. Clin Chem Lab Med 2000, 38:731–736.

    Article  PubMed  CAS  Google Scholar 

  47. van Venrooij FV, Stolk RP, Banga JD, et al.: Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003, 26:1216–1223.

    Article  PubMed  Google Scholar 

  48. Freeman DJ, Samani NJ, Wilson V, et al.: A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. Eur Heart J 2003, 24:1833–1842.

    Article  PubMed  CAS  Google Scholar 

  49. de Grooth GJ, Zerba KE, Huang SP, et al.: The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy. J Am Coll Cardiol 2004, 43:854–857.

    Article  PubMed  CAS  Google Scholar 

  50. Winkelmann BR, Hoffmann MM, Nauck M, et al.: Haplotypes of the cholesteryl ester transfer protein gene predict lipidmodifying response to statin therapy. Pharmacogenomics J 2003, 3:284–296.

    Article  PubMed  CAS  Google Scholar 

  51. Marian AJ, Safavi F, Ferlic L, et al.: Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000, 35:89–95.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Human Genetics Center, Health Science Center at Houston, University of Texas, 1200 Hermann Pressler, 77030, Houston, TX, USA

    Eric Boerwinkle PhD

Authors
  1. Anke-Hilse Maitland-van der Zee PharmD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Boerwinkle PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zee, AH.Mv.d., Boerwinkle, E. Pharmacogenetics of response to statins: Where do we stand?. Curr Atheroscler Rep 7, 204–208 (2005). https://doi.org/10.1007/s11883-005-0007-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-005-0007-3

Keywords

Search

Navigation